NCT02532140View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
Healthy
Interventions
DRUG

WCK 5107 250 mg to 2000 mg

DRUG

Cefepime 2000 mg

DRUG

WCK 5107 1000/2000 mg with Cefepime 2000 mg combination

DRUG

Placebo

Trial Locations (1)

66211

Quintiles, Overland Park

Sponsors

Lead Sponsor

Wockhardt
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Wockhardt

INDUSTRY